Phase IV, Two-arm, Open-label, Single-centre Randomised Pilot Study to Assess the Feasibility of Immediate or Deferred Switching of HIV-infected Individuals Intolerant of Efavirenz, Ritonavir-boosted Lopinavir or Ritonavir-boosted Darunavir
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- The improvement of NNRTI/PI associated toxicity after 4 weeks of therapy with ritonavir boosted darunavir.
研究概览
简要总结
The purpose of the study is to examine the effects of switching from antiretroviral combinations that includes efavirenz (Sustiva®), lopinavir/ritonavir (Kaletra®) or atazanavir/ritonavir (Reyataz®/Norvir®) in individuals experiencing side effects from one of these agents, and replacing these with a new HIV medication called Darunavir also given with ritonavir (Norvir®).
The study will primarily investigate the effect of change in medication on the subjects viral load (the levels of the HIV virus in the blood), on immunological parameters (CD4 count) and on other safety parameters (such as cholesterol) and also quality of life.
详细描述
The advent of highly active antiretroviral therapy (HAART) has revolutionised the treatment of HIV disease, with both patients and physicians enjoying the marked reductions in HIV related morbidity and mortality. However, as long term therapeutic success has become a realistic goal of treatment, there are increasing reports of toxicities associated with therapy.
Indeed since the advent of HAART the major reason for change in therapy has not been a lack of efficacy associated with drug regimens but the toxicity associated with individual agents. Although the potential adverse events associated with antiretrovirals are manifold there are signature treatment-limiting toxicities associated with particular agents such as EFV and CNS/neuropsychiatric adverse events, LPV/r and gastrointestinal toxicity and ATV/r and jaundice.
A recent study performed at the Chelsea and Westminster hospital showed that 61% of regimen switches were due to toxicity and the majority of these occurred after 12 weeks of therapy.
Darunavir is a recently licensed protease inhibitor which requires ritonavir boosting.Currently DRV/r is licensed for use in treatment-experienced individuals. In triple-class experienced patients ritonavir boosted darunavir has been associated with greater viral load reductions when combined with optimized background (OB) than OB alone. A study of PI experienced patients randomized to receive Kaletra or ritonavir boosted darunavir with optimised background therapy showed significantly higher rates of virological suppression in the DRV/r arm; rates of toxicities were similar overall but less diarrhoea in the DRV/r than the Kaletra arm. Darunavir is licensed twice daily and has a high barrier to the development of resistance. DRV/r dosed at 800/100mg once daily has been compared with LPV/r in treatment-naïve subjects. DRV/r was non-inferior to LPV/r overall and performed significantly better than LPV once daily and in subjects with a high baseline viral load. DRV/r and LPV/r have also been compared head to head in 'early'treatment-experienced patients (failing first or second line therapy but LPV-naive). Overall DRV/r exhibited superiority to LPV/r with 77% and 67% achieving viral suppression to less than 50 copies/ml by intent-to-treat analysis respectively (95% confidence interval for the difference 2-17%; p <0.0001). Animal studies have shown a low risk of teratogenesis associated with DRV.
This study aims to investigate whether substitution of NNRTI/PI with ritonavir boosted darunavir leads to resolution of toxicity associated with these drugs, continued virological suppression and immunological reconstitution and whether this is associated with an improvement in quality of life.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV-1 infected as documented by a licensed HIV-1 antibody ELISA test
- •Subject is currently on an antiretroviral regimen comprising of at least three licensed antiretroviral agents including efavirenz, ritonavir-boosted lopinavir or ritonavir-boosted atazanavir
- •Subject is virologically suppressed with a viral load < 50 copies/ml
- •Subject has a CD4+ count above 50 cells/ml
- •If subject is a female of childbearing potential, she must agree to use a double barrier method of contraception
- •No previous exposure to darunavir
排除标准
- •Pregnant or lactating women
- •Any female of childbearing potential not using effective birth control methods or not willing to continue practicing these birth control methods during the trial and for at least 30 days after the end of the trial (or after last intake of investigational ARVs)
- •Heterosexually active male subject not using effective birth control methods or not willing to continue practicing these birth control methods during the trial and until 30 days after the end of the trial (or after last intake of investigational ARVs)
研究组 & 干预措施
Group 1
Immediate switch from NNRTI/PI to DRV/r
干预措施: darunavir (Drug)
Group 2
Switch after 10 weeks from NNRTI/PI to DRV/r
干预措施: ritonavir (Drug)
结局指标
主要结局
The improvement of NNRTI/PI associated toxicity after 4 weeks of therapy with ritonavir boosted darunavir.
时间窗: 20 days
次要结局
- Viral load suppression below 50 copies/ml post switch(between 20 and 60 days)
- Viral load < 400 copies/ml post switch(between 20 and 60 days)
- Toxicity(60 days)
- Health related quality of life questionnaires(Baseline, 20 and 60 days)
- Changes in fasting triglycerides post switch(20 days and 60 days)
- Adherence as measured via questionnaire(baseline, 20 days and 60 days)
- Tolerability as measured by tolerability index questionnaire (HIV patients symptoms profile(baseline, 20 days and 40 days)